Bertucci François, Salas Sébastien, Eysteries Séverine, Nasser Valéry, Finetti Pascal, Ginestier Christophe, Charafe-Jauffret Emmanuelle, Loriod Béatrice, Bachelart Loïc, Montfort Jérôme, Victorero Geneviève, Viret Frédéric, Ollendorff Vincent, Fert Vincent, Giovaninni Marc, Delpero Jean-Robert, Nguyen Catherine, Viens Patrice, Monges Geneviève, Birnbaum Daniel, Houlgatte Rémi
Département d'Oncologie Moléculaire, Institut Paoli-Calmettes and U119 Inserm, IFR57, Marseille, France.
Oncogene. 2004 Feb 19;23(7):1377-91. doi: 10.1038/sj.onc.1207262.
Different diagnostic and prognostic groups of colorectal carcinoma (CRC) have been defined. However, accurate diagnosis and prediction of survival are sometimes difficult. Gene expression profiling might improve these classifications and bring new insights into underlying molecular mechanisms. We profiled 50 cancerous and noncancerous colon tissues using DNA microarrrays consisting of approximately 8000 spotted human cDNA. Global hierarchical clustering was to some extent able to distinguish clinically relevant subgroups, normal versus cancer tissues and metastatic versus nonmetastatic tumours. Supervised analyses improved these segregations by identifying sets of genes that discriminated between normal and tumour tissues, tumours associated or not with lymph node invasion or genetic instability, and tumours from the right or left colon. A similar approach identified a gene set that divided patients with significantly different 5-year survival (100% in one group and 40% in the other group; P=0.005). Discriminator genes were associated with various cellular processes. An immunohistochemical study on 382 tumour and normal samples deposited onto a tissue microarray subsequently validated the upregulation of NM23 in CRC and a downregulation in poor prognosis tumours. These results suggest that microarrays may provide means to improve the classification of CRC, provide new potential targets against carcinogenesis and new diagnostic and/or prognostic markers and therapeutic targets.
结直肠癌(CRC)已被定义为不同的诊断和预后组。然而,准确诊断和预测生存率有时会很困难。基因表达谱分析可能会改善这些分类,并为潜在的分子机制带来新的见解。我们使用由约8000个点样的人类cDNA组成的DNA微阵列对50个癌性和非癌性结肠组织进行了分析。全局层次聚类在一定程度上能够区分临床相关亚组、正常组织与癌组织以及转移瘤与非转移瘤。通过识别区分正常组织和肿瘤组织、与淋巴结侵袭或基因不稳定相关或不相关的肿瘤以及右半结肠或左半结肠癌组织的基因集,监督分析改善了这些分离。类似的方法识别出了一组基因,该基因集将5年生存率差异显著的患者分为两组(一组为100%,另一组为40%;P = 0.005)。鉴别基因与各种细胞过程相关。随后,对组织微阵列上的382个肿瘤和正常样本进行的免疫组化研究证实了NM23在CRC中的上调以及在预后不良肿瘤中的下调。这些结果表明,微阵列可能提供改善CRC分类的方法,提供针对致癌作用的新潜在靶点以及新的诊断和/或预后标志物及治疗靶点。